Reviewed May 2012
What is the official name of the APP gene?
The official name of this gene is “amyloid beta precursor protein.”
APP is the gene's official symbol. The APP gene is also known by other names, listed below.
What is the normal function of the APP gene?
The APP gene provides instructions for making a protein called amyloid precursor protein. This protein is found in many tissues and organs, including the brain and spinal cord (central nervous system). Little is known about the function of amyloid precursor protein. Researchers speculate that it may bind to other proteins on the surface of cells or help cells attach to one another. Studies suggest that in the brain, it helps direct the movement (migration) of nerve cells (neurons) during early development.
Amyloid precursor protein is cut by enzymes to create smaller fragments (peptides), some of which are released outside the cell. Two of these fragments are called soluble amyloid precursor protein (sAPP) and amyloid beta (β) peptide. Recent evidence suggests that sAPP has growth-promoting properties and may play a role in the formation of nerve cells (neurons) in the brain both before and after birth. The sAPP peptide may also control the function of certain other proteins by turning off (inhibiting) their activity. Amyloid β peptide is likely involved in the ability of neurons to change and adapt over time (plasticity). Other functions of sAPP and amyloid β peptide are under investigation.
Does the APP gene share characteristics with other genes?
The APP gene belongs to a family of genes called endogenous ligands (endogenous ligands).
A gene family is a group of genes that share important characteristics. Classifying individual genes into families helps researchers describe how genes are related to each other. For more information, see What are gene families? (http://ghr.nlm.nih.gov/handbook/howgeneswork/genefamilies) in the Handbook.
How are changes in the APP gene related to health conditions?
- Alzheimer disease - caused by mutations in the APP gene
More than 50 different mutations in the APP gene can cause early-onset Alzheimer disease, which begins before age 65. These mutations are responsible for less than 10 percent of all early-onset cases of the disorder.
The most common APP mutation changes one of the protein building blocks (amino acids) in the amyloid precursor protein. This mutation replaces the amino acid valine with the amino acid isoleucine at protein position 717 (written as Val717Ile or V717I). Mutations in the APP gene can lead to an increased amount of the amyloid β peptide or to the production of a slightly longer and stickier form of the peptide. When these protein fragments are released from the cell, they can accumulate in the brain and form clumps called amyloid plaques. These plaques are characteristic of Alzheimer disease. A buildup of toxic amyloid β peptide and amyloid plaques may lead to the death of neurons and the progressive signs and symptoms of this disorder.
- hereditary cerebral amyloid angiopathy - caused by mutations in the APP gene
At least six mutations in the APP gene have been found to cause hereditary cerebral amyloid angiopathy, a condition characterized by stroke and a decline in intellectual function (dementia), which begins in mid-adulthood. These mutations change single amino acids in the amyloid precursor protein. All of the APP gene mutations that cause hereditary cerebral amyloid angiopathy lead to changes near the beginning of the protein sequence. Each of these mutations causes a different type of the condition. The Dutch type, the most common of all the types, is caused by the replacement of the amino acid glutamic acid with the amino acid glutamine at position 22 in the protein sequence (written as Glu22Gln or E22Q). The Italian type and Arctic type are also caused by changes to glutamic acid at position 22. In the Italian type, glutamic acid is replaced with the amino acid lysine (written as Glu22Lys or E22K) and in the Arctic type, glutamic acid is replaced with the amino acid glycine (written as Glu22Gly or E22G). The Flemish type is caused by replacement of the amino acid alanine with glycine at position 21 (written as Ala21Gly or A21G). In the Iowa type, the amino acid aspartic acid is switched with the amino acid asparagine at position 23 (written as Asp23Asn or D23N). The Piedmont type of hereditary cerebral amyloid angiopathy is caused by the replacement of the amino acid leucine at position 34 with the amino acid valine (written as Leu34Val or L34V).
The result of all of these mutations is the production of an amyloid β peptide that is more prone to cluster together (aggregate) than the normal peptide. The aggregated protein forms amyloid deposits known as plaques that accumulate in the blood vessels of the brain. The amyloid plaques replace the muscle fibers and elastic fibers that give blood vessels flexibility, causing the blood vessels to become weak and prone to breakage. In the brain, such a break causes bleeding (hemorrhagic stroke), which can lead to brain damage and dementia. Amyloid plaques in specific parts of the brain can interfere with brain function, leading to seizures, movement problems, and other neurological features in some people with hereditary cerebral amyloid angiopathy.
Where is the APP gene located?
Cytogenetic Location: 21q21.3
Molecular Location on chromosome 21: base pairs 25,880,550 to 26,171,128
(Homo sapiens Annotation Release 107, GRCh38.p2) (NCBI (http://www.ncbi.nlm.nih.gov/gene/351))
The APP gene is located on the long (q) arm of chromosome 21 at position 21.3.
More precisely, the APP gene is located from base pair 25,880,550 to base pair 26,171,128 on chromosome 21.
See How do geneticists indicate the location of a gene? (http://ghr.nlm.nih.gov/handbook/howgeneswork/genelocation) in the Handbook.
Where can I find additional information about APP?
You and your healthcare professional may find the following resources about APP helpful.
Educational resources - Information pages
- Basic Neurochemistry (sixth edition, 2006): Alzheimer's Disease Is the Most Common Neurodegenerative Disorder (http://www.ncbi.nlm.nih.gov/books/NBK27944/)
- Madame Curie Bioscience Database: Overview Αβ Metabolism: From Alzheimer Research to Brain Aging Control (http://www.ncbi.nlm.nih.gov/books/NBK6311/)
- Madame Curie Bioscience Database: Potential Role of Endogenous and Exogenous Ab Binding Molecules in Ab Clearance and Metabolism (http://www.ncbi.nlm.nih.gov/books/NBK6203/)
- Gene Reviews - Clinical summary (http://www.ncbi.nlm.nih.gov/books/NBK1236)
Genetic Testing Registry - Repository of genetic test information
- GTR: Genetic tests for APP (http://www.ncbi.nlm.nih.gov/gtr/tests/?term=351%5Bgeneid%5D)
You may also be interested in these resources, which are designed for genetics professionals and researchers.
- PubMed - Recent literature (http://www.ncbi.nlm.nih.gov/pubmed?term=%28%28APP%5BTI%5D%29%20OR%20%28amyloid%20beta%20%20%20precursor%20protein%5BTI%5D%29%29%20AND%20%28%28Genes%5BMH%5D%29%20OR%20%28Genetic%20Phenomena%5BMH%5D%29%29%20AND%20english%5Bla%5D%20AND%20human%5Bmh%5D%20AND%20%22last%201080%20days%22%5Bdp%5D)
- OMIM - Genetic disorder catalog (http://omim.org/entry/104760)
Research Resources - Tools for researchers
- Alzheimer Disease & Frontotemporal Dementia Mutation Database (http://www.molgen.ua.ac.be/ADmutations/Default.cfm?MT=1&ML=1&Page=MutByQuery&Query=tblContexts.ID=3&Selection=Gene%20=%20APP)
- Alzheimer Research Forum: AlzGene database (http://www.alzgene.org/geneoverview.asp?geneid=235)
- Atlas of Genetics and Cytogenetics in Oncology and Haematology (http://atlasgeneticsoncology.org/Genes/GC_APP.html)
- HGNC Gene Family: Endogenous ligands (http://www.genenames.org/cgi-bin/genefamilies/set/542)
- HGNC Gene Symbol Report (http://www.genenames.org/cgi-bin/gene_symbol_report?q=data/hgnc_data.php&hgnc_id=620)
- NCBI Gene (http://www.ncbi.nlm.nih.gov/gene/351)
What other names do people use for the APP gene or gene products?
- amyloid beta (A4) precursor protein
- amyloid beta-peptide
- amyloid beta-protein precursor
- amyloid precursor protein
- cerebral vascular amyloid peptide
- protease nexin 2
- protease nexin-II
See How are genetic conditions and genes named? (http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/naming) in the Handbook.
What glossary definitions help with understanding APP?
amino acid ;
amyloid beta-protein ;
aspartic acid ;
central nervous system ;
glutamic acid ;
hemorrhagic stroke ;
nervous system ;
protein sequence ;
You may find definitions for these and many other terms in the Genetics Home Reference
- Bornebroek M, De Jonghe C, Haan J, Kumar-Singh S, Younkin S, Roos R, Van Broeckhoven C. Hereditary cerebral hemorrhage with amyloidosis Dutch type (AbetaPP 693): decreased plasma amyloid-beta 42 concentration. Neurobiol Dis. 2003 Dec;14(3):619-23. (http://www.ncbi.nlm.nih.gov/pubmed/14678776?dopt=Abstract)
- Caillé I, Allinquant B, Dupont E, Bouillot C, Langer A, Müller U, Prochiantz A. Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development. 2004 May;131(9):2173-81. Epub 2004 Apr 8. (http://www.ncbi.nlm.nih.gov/pubmed/15073156?dopt=Abstract)
- Conti L, Cattaneo E. Controlling neural stem cell division within the adult subventricular zone: an APPealing job. Trends Neurosci. 2005 Feb;28(2):57-9. Review. (http://www.ncbi.nlm.nih.gov/pubmed/15667924?dopt=Abstract)
- Cordy JM, Hooper NM, Turner AJ. The involvement of lipid rafts in Alzheimer's disease. Mol Membr Biol. 2006 Jan-Feb;23(1):111-22. Review. (http://www.ncbi.nlm.nih.gov/pubmed/16611586?dopt=Abstract)
- Edwards-Lee T, Ringman JM, Chung J, Werner J, Morgan A, St George Hyslop P, Thompson P, Dutton R, Mlikotic A, Rogaeva E, Hardy J. An African American family with early-onset Alzheimer disease and an APP (T714I) mutation. Neurology. 2005 Jan 25;64(2):377-9. (http://www.ncbi.nlm.nih.gov/pubmed/15668448?dopt=Abstract)
- Fernandez-Madrid I, Levy E, Marder K, Frangione B. Codon 618 variant of Alzheimer amyloid gene associated with inherited cerebral hemorrhage. Ann Neurol. 1991 Nov;30(5):730-3. (http://www.ncbi.nlm.nih.gov/pubmed/1763898?dopt=Abstract)
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002 Jul 19;297(5580):353-6. Review. Erratum in: Science 2002 Sep 27;297(5590):2209. (http://www.ncbi.nlm.nih.gov/pubmed/12130773?dopt=Abstract)
- Harman D. Alzheimer's disease pathogenesis: role of aging. Ann N Y Acad Sci. 2006 May;1067:454-60. Review. (http://www.ncbi.nlm.nih.gov/pubmed/16804026?dopt=Abstract)
- Kerr ML, Small DH. Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development. J Neurosci Res. 2005 Apr 15;80(2):151-9. Review. (http://www.ncbi.nlm.nih.gov/pubmed/15672415?dopt=Abstract)
- Levy E, Prelli F, Frangione B. Studies on the first described Alzheimer's disease amyloid beta mutant, the Dutch variant. J Alzheimers Dis. 2006;9(3 Suppl):329-39. Review. (http://www.ncbi.nlm.nih.gov/pubmed/16914871?dopt=Abstract)
- Maat-Schieman M, Roos R, van Duinen S. Hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neuropathology. 2005 Dec;25(4):288-97. Review. (http://www.ncbi.nlm.nih.gov/pubmed/16382777?dopt=Abstract)
- Majersik JJ, Skalabrin EJ. Single-gene stroke disorders. Semin Neurol. 2006 Feb;26(1):33-48. Review. (http://www.ncbi.nlm.nih.gov/pubmed/16479442?dopt=Abstract)
- NCBI Gene (http://www.ncbi.nlm.nih.gov/gene/351)
- Obici L, Demarchi A, de Rosa G, Bellotti V, Marciano S, Donadei S, Arbustini E, Palladini G, Diegoli M, Genovese E, Ferrari G, Coverlizza S, Merlini G. A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann Neurol. 2005 Oct;58(4):639-44. (http://www.ncbi.nlm.nih.gov/pubmed/16178030?dopt=Abstract)
- Papassotiropoulos A, Fountoulakis M, Dunckley T, Stephan DA, Reiman EM. Genetics, transcriptomics, and proteomics of Alzheimer's disease. J Clin Psychiatry. 2006 Apr;67(4):652-70. Review. (http://www.ncbi.nlm.nih.gov/pubmed/16669732?dopt=Abstract)
- Rocchi A, Pellegrini S, Siciliano G, Murri L. Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull. 2003 Jun 30;61(1):1-24. Review. (http://www.ncbi.nlm.nih.gov/pubmed/12788204?dopt=Abstract)
- Salameh MA, Robinson JL, Navaneetham D, Sinha D, Madden BJ, Walsh PN, Radisky ES. The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin. J Biol Chem. 2010 Jan 15;285(3):1939-49. doi: 10.1074/jbc.M109.057216. Epub 2009 Nov 17. (http://www.ncbi.nlm.nih.gov/pubmed/19920152?dopt=Abstract)
- Wolfe MS, Guénette SY. APP at a glance. J Cell Sci. 2007 Sep 15;120(Pt 18):3157-61. Review. (http://www.ncbi.nlm.nih.gov/pubmed/17878232?dopt=Abstract)
- Zhang H, Ma Q, Zhang YW, Xu H. Proteolytic processing of Alzheimer's β-amyloid precursor protein. J Neurochem. 2012 Jan;120 Suppl 1:9-21. doi: 10.1111/j.1471-4159.2011.07519.x. Epub 2011 Nov 28. Review. (http://www.ncbi.nlm.nih.gov/pubmed/22122372?dopt=Abstract)
The resources on this site should not be used as a substitute for
professional medical care or advice. Users seeking information about
a personal genetic disease, syndrome, or condition should consult with a qualified
See How can I find a genetics professional in my area? (http://ghr.nlm.nih.gov/handbook/consult/findingprofessional) in the Handbook.